Laura E Case Selected Research

human GAA protein (Myozyme)

1/2020	Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
1/2017	Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.
4/2015	Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
9/2012	The emerging phenotype of long-term survivors with infantile Pompe disease.
3/2012	Early cognitive development in children with infantile Pompe disease.
1/2012	Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
12/2008	Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study.
5/2007	Fractures in children with Pompe disease: a potential long-term complication.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura E Case Research Topics

Disease

20	Glycogen Storage Disease Type II (Pompe's Disease) 01/2020 - 05/2007
5	Muscle Weakness 12/2021 - 05/2011
2	Hepatomegaly 12/2021 - 11/2021
2	Glycogen Storage Disease IIIA 11/2021 - 11/2012
2	Spasm (Spasms) 01/2020 - 01/2018
2	Tremor (Tremors) 01/2020 - 01/2018
2	Contracture 01/2019 - 10/2018
1	Cerebral Palsy (Spastic Diplegia) 12/2022
1	Disease Progression 12/2021
1	Glycogen Storage Disease IIIB 12/2021
1	Fibrosis (Cirrhosis) 12/2021
1	Glycogen Storage Disease Type III (Cori's Disease) 12/2021
1	Portal Hypertension 12/2021
1	Liver Diseases (Liver Disease) 12/2021
1	Hypoglycemia (Reactive Hypoglycemia) 11/2021
1	Glycogen Storage Disease (Glycogenosis) 11/2021
1	Muscle Spasticity (Spastic) 01/2021
1	Muscular Diseases (Myopathy) 01/2020
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2019
1	Congenital Abnormalities (Deformity) 10/2018
1	Muscle Hypotonia (Hypotonia) 01/2017
1	Osteomalacia 01/2016
1	Rickets (Rachitis) 01/2016
1	Hypophosphatasia 01/2016
1	Rare Diseases (Rare Disease) 01/2016
1	Bone Fractures (Bone Fracture) 01/2016
1	Neuromuscular Diseases (Neuromuscular Disease) 11/2015
1	Brown-Vialetto-Van Laere syndrome 10/2015
1	Cardiomyopathies (Cardiomyopathy) 05/2007

Drug/Important Bio-Agent (IBA)

8	AcidsIBA 01/2020 - 05/2007
8	human GAA protein (Myozyme)FDA Link 01/2020 - 05/2007
7	GlycogenIBA 12/2021 - 05/2011
6	GlucosidasesIBA 01/2020 - 05/2011
4	EnzymesIBA 12/2021 - 05/2007
2	Protons (Proton)IBA 11/2021 - 05/2015
2	Biomarkers (Surrogate Marker)IBA 11/2021 - 01/2020
2	Albuterol (Salbutamol)FDA LinkGeneric 01/2020 - 05/2014
2	alpha-Glucosidases (Acid Maltase)IBA 01/2017 - 05/2007
1	Hypoglycemic Agents (Hypoglycemics)IBA 12/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2020
1	ClenbuterolIBA 01/2018
1	MM Form Creatine KinaseIBA 01/2018
1	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 01/2016
1	Riboflavin (Vitamin B2)FDA LinkGeneric 10/2015
1	CationsIBA 05/2014
1	IGF Type 2 Receptor (Insulin-Like-Growth-Factor II Receptor)IBA 05/2014
1	AntibodiesIBA 07/2012

Therapy/Procedure

11	Enzyme Replacement Therapy 01/2020 - 05/2007
4	Physical Therapy Modalities (Physical Therapy Technique) 11/2021 - 11/2015
3	Breathing Exercises 01/2020 - 01/2014
3	Therapeutics 01/2020 - 05/2014
1	Aftercare (After-Treatment) 12/2022
1	Diet Therapy (Therapy, Diet) 12/2021
1	Intravenous Infusions 01/2021
1	Contraindications 01/2020
1	Self-Help Devices (Assistive Technology) 10/2018